Steve McCairns Joins Expanding PCI Team as UK Director of Operations
News Apr 02, 2014
Packaging Coordinators, Inc. (PCI) has welcomed Steve McCairns as Director of Operations for its UK business.
PCI is a global leader for packaging services, supporting both pharmaceutical and biotech customers in each stage of the development and commercialization of drug products. In addition to packaging services, PCI provides global storage and distribution services for clinical trial materials.
As a global organization, PCI operates four clinical and commercial sites in the UK with eleven facilities in three locations throughout the United States. The UK site recently announced investment in expansion of on-site Cold Chain packaging capabilities.
McCairns joins PCI with a long and distinguished career in pharmaceutical and healthcare operations, firstly with Amersham PLC and since 2004 with GE Healthcare, holding various operations, quality and international project management roles including Site Director of their Gloucester Manufacturing site since 2008.
McCairns is a Lean Six Sigma practitioner having achieved his Black Belt certification and is a graduate of GE’s prestigious Executive Lean Leadership Development Programme which involved leading Kaizen internationally - throughout Europe, US and Asia; as such he has extensive experience of leveraging Lean Manufacturing and applying Six Sigma principles within a cGMP environment.
Holding a Masters degree in Business Administration from the University of Gloucestershire, McCairns is also in the final stages of completing a Doctorate in Business Administration.
“I am delighted to have someone of Steve’s caliber join the PCI management team,” states Sue Miles, Managing Director PCI UK. “His expertise and skill set are significant additions to our global business, and his vision will help transform this business as we look to grow and expand our services in the healthcare market.”
Targeted Drug Could be Used to Treat Advanced Cancers Located Anywhere in the BodyNews
A new targeted drug could be used to treat a small number of advanced cancers no matter where they grow in the body.READ MORE
Investigational Drug for Melanoma Shows Promise in Early-Stage StudyNews
An investigational compound designed to block a hyperactive cell growth signal in advanced melanoma and other cancers has shown some promise in an early-stage clinical trial researchers have reported.READ MORE
Scientists Report The Development of a Potent New Medicine to Fight AddictionNews
Scientists report the development of a potent new medicine to fight addiction.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018